Core Insights - The study indicates that SUBLOCADE, an extended-release buprenorphine injection, may significantly reduce staff time and associated costs in jails and prisons compared to other medications for opioid use disorder (MOUD) [1][2][3] Group 1: Cost Impact Model Findings - The model estimates that using monthly injectable buprenorphine requires fewer staff hours than other MOUD treatments, with reductions of 318 hours compared to methadone, 747 hours compared to oral buprenorphine, 192 hours compared to weekly extended-release buprenorphine, and 6 hours compared to extended-release naltrexone [7] - The estimated monthly cost savings from reduced staff time range from $23 to $22,148, with the largest savings resulting from the elimination of daily observed dosing and patient escorts [7] Group 2: Staffing Challenges in Correctional Facilities - Correctional facilities are facing ongoing staffing constraints as the demand for MOUD continues to grow, with nearly half of U.S. jails and prisons citing staffing as a primary barrier to providing MOUD [2][3] - The findings suggest that monthly injectable buprenorphine can alleviate the dosing burden and staff involvement, allowing facilities to operate more efficiently while expanding access to evidence-based care [2][3] Group 3: Study Background and Limitations - The study was funded by Indivior and conducted in collaboration with Veradigm and researchers from the University of Kentucky College of Medicine [4] - Limitations of the study include the exclusion of medication acquisition costs and some administration times based on assumptions due to a lack of available data [3]

Core Insights - StoneX Group Inc. has acquired WCS International Ltd, enhancing its offerings in the wholesale banknotes trading and distribution sector [1][2] - The acquisition aims to strengthen StoneX's relevance to financial institutions by complementing its existing cross-border payments business [1][3] Company Overview - StoneX Group Inc. operates a global financial services network, connecting various entities to the global market ecosystem through digital platforms and execution services [4][5] - The company serves over 80,000 commercial and institutional clients, along with more than 260,000 retail accounts across six continents [5] WCSI Overview - WCS International Ltd was established in 2022, focusing on wholesale banknotes trading services for banks and financial institutions [2][6] - The company has built strategic alliances with established banknote wholesalers and retailers, providing access to over 90 global currencies [7] Strategic Benefits - The acquisition will leverage StoneX's global correspondent banking relationships and extensive currency access, positioning it as a global non-bank provider of banknotes, payments, and foreign exchange [3] - Angela Smith, CEO of WCSI, emphasized that joining StoneX will provide the necessary balance sheet strength and global reach to accelerate growth [4][6]

Core Insights - LPL Financial LLC has welcomed financial advisor Tasha Coleman, founder of Five Star Wealth Planning, to its broker-dealer and Registered Investment Advisor platform, managing approximately $185 million in advisory, brokerage, and retirement plan assets [1][7] Company Overview - LPL Financial Holdings Inc. is one of the fastest-growing wealth management firms in the U.S., supporting over 32,000 financial advisors and approximately 1,200 financial institutions, with around $2.4 trillion in brokerage and advisory assets for about 8 million Americans [6] Advisor Transition - Tasha Coleman brings over 20 years of experience in the industry, focusing on retirement preparation and wealth transfer planning, emphasizing a relational and education-driven approach [2][3] - The transition to LPL is described by Coleman as centered on enhancing client relationships while leveraging superior technology and cybersecurity protections [3][4] Technology and Innovation - Coleman highlighted LPL's advanced technology and commitment to innovation as key factors in her decision to join, stating that it is essential for aligning clients with a firm that prioritizes the advisor-client relationship [4] - LPL's investment in technology and cybersecurity is seen as a significant advantage for advisors and their clients [4] Community Focus - Coleman expressed that the transition allows Five Star Wealth Planning to continue serving multigenerational families while remaining rooted in their community [4] - The firm aims to maintain a boutique feel with the resources of a larger firm, reinforcing their commitment to personalized service [3][4] Leadership Perspective - Scott Posner, managing director of business development at LPL, praised Coleman's dedication to client education and personalized planning, aligning with LPL's mission to empower advisors [4]

Core Insights - Ernexa Therapeutics is advancing its lead product candidate ERNA-101 towards a first-in-human clinical trial for platinum-resistant ovarian cancer, with an IND submission expected in Q3 2026 and trial initiation planned for Q4 2026 [1][2][14] - The company has reported significant preclinical data showing durable tumor regressions and prolonged survival in ovarian cancer models when ERNA-101 is combined with PD-1 blockade, indicating its potential as a foundational immunotherapy platform [3][8] - Ernexa is also developing ERNA-201, an engineered anti-inflammatory therapy targeting autoimmune diseases, alongside the advancement of ERNA-101 [5][12] Company Progress - Ernexa has streamlined operations, reducing general and administrative expenses by approximately 61% year over year while maintaining focus on core programs [9] - The company completed Proof of Principle studies for both ERNA-101 and ERNA-201 and successfully held a Pre-IND meeting with the FDA for ERNA-101 [9][10] Upcoming Milestones - Key milestones include the completion of ERNA-101 clinical manufacturing process development in Q2 2026, IND-enabling preclinical studies in Q3 2026, and the initiation of the first-in-human Phase 1 clinical study in Q4 2026 [14] - Initial clinical data readout from ERNA-101 is expected in the first half of 2027, with advancement into Phase 2 trials anticipated in the second half of 2027 [14]

Core Viewpoint - Stack Capital Group Inc. has successfully closed its private placement, the LIFE Offering, raising gross proceeds of $8,750,000 by issuing 466,666 units at a price of $18.75 per unit [1][2]. Group 1: Offering Details - The LIFE Offering was led by Canaccord Genuity Corp. as the lead agent and sole bookrunner, with a syndicate of agents including Raymond James Ltd., TD Securities Inc., and RBC Capital Markets [2]. - A concurrent private placement is expected to close around April 10, 2026, with conditional approval from the Toronto Stock Exchange for the listing of the Unit Shares and Warrants [3]. - Each unit consists of one common share and one-quarter of a common share purchase warrant, with each warrant allowing the purchase of one common share at an exercise price of $23.00 for 24 months [4]. Group 2: Use of Proceeds and Fees - The net proceeds from the LIFE Offering will be utilized for investments in line with the company's investment principles and for general corporate and working capital purposes [6]. - The company paid a cash fee of 5.0% of the gross proceeds to the agents and a corporate finance fee of $100,000 to the lead agent upon closing [6]. Group 3: Company Overview - Stack Capital Group Inc. is an investment holding company focused on investing in equity, debt, and other securities of growth-to-late-stage private businesses, providing shareholders with exposure to a diversified private investment portfolio [8]. - The company aims to maximize long-term performance through a portfolio of high-growth businesses that are not widely available to most Canadian investors [8].

Core Viewpoint - The Annual General Meeting of Shareholders for AS Tallinna Vesi is scheduled for 23 April 2026, with key agenda items including the approval of the Annual Report for 2025, profit distribution, and changes in the Supervisory Council [2][4][5]. Group 1: Meeting Details - The Annual General Meeting will take place at the Blue Auditorium of the Ülemiste Water Treatment Plant, starting at 10:00 (UTC+3) on 23 April 2026, with registration opening at 09:30 [2]. - The list of shareholders entitled to vote will be established on 16 April 2026 [3]. Group 2: Agenda Items - The Supervisory Council proposes the approval of the consolidated Annual Report for 2025 [4]. - The net profit for 2025 is reported at €14,242 thousand, with a proposal to distribute €11,400 thousand as dividends, equating to €0.57 per share [5]. - The remainder of the retained earnings will remain undistributed, and no allocations will be made to the reserve capital [5]. Group 3: Supervisory Council Changes - The proposal includes recalling Mart Mägi from the Supervisory Council effective 23 April 2026 [7]. - Priit Lello is proposed for election to the Supervisory Council for a three-year term starting 24 April 2026 [8]. - Gerli Kivisoo's term is proposed to be extended for an additional three years starting 2 June 2026 [9]. Group 4: Gender Balance Target - A proposal to set a gender balance target is included, aiming for at least 33% of seats on the Management Board and Supervisory Council to be held by members of the underrepresented sex [10]. Group 5: Shareholder Participation - Shareholders holding at least 1/20 of the share capital can propose additional agenda items or draft resolutions, with deadlines set for 8 April 2026 and 20 April 2026 respectively [11]. - Shareholders may request information from the Management Board regarding the Company's activities, with a deadline for questions set for 22 April 2026 [12]. Group 6: Voting and Proxies - Electronic voting will be available until 17:00 (UTC+3) on 22 April 2026, and shareholders voting electronically will be considered present at the meeting [15]. - Shareholders must bring valid identification and, if applicable, a digitally signed or notarised proxy to attend the meeting [16]. Group 7: Publication and Contact Information - The notice for the General Meeting will be published in the daily newspaper Postimees on 31 March 2026, and minutes will be available on the Company's website within seven days post-meeting [17].

Core Viewpoint - Foremost Clean Energy Ltd. has successfully completed a bought deal private placement, raising gross proceeds of C$5,746,680 to support its exploration activities in uranium and lithium sectors [1][2]. Group 1: Offering Details - The Offering involved the issuance of 1,690,200 flow-through units at a price of C$3.40 per unit, which includes 72,200 units from a partial exercise of the Underwriter's option [2]. - Each flow-through unit consists of one common share and one half of a common share purchase warrant, with the warrants exercisable at C$4.40 per share until March 31, 2028 [2]. - The Underwriter received a cash commission of 6.0% on gross proceeds, reduced to 2.0% for certain purchasers on a President's List, along with Broker Warrants equal to 6.0% of the units sold [3]. Group 2: Use of Proceeds - The gross proceeds will be used to incur Canadian exploration expenses qualifying as flow-through critical mineral mining expenditures on the Company's properties in Saskatchewan and Manitoba by December 31, 2027 [6]. - The Company will renounce all qualifying expenditures in favor of the purchasers effective December 31, 2026, with indemnification provided for any additional taxes due to failure in renouncing [6]. Group 3: Company Overview - Foremost Clean Energy Ltd. is focused on uranium and lithium exploration, strategically positioned to meet the growing demand for carbon-free energy [9]. - The Company holds an option to earn up to 70% interest in 10 uranium properties in the Athabasca Basin, covering over 330,000 acres, and employs a data-driven exploration strategy [10]. - Additionally, Foremost has lithium projects spanning over 43,000 acres in Manitoba, contributing to its portfolio of critical materials for electrification and energy storage [11].

Core Insights - LifeMD has launched a subscription program for Novo Nordisk's Wegovy® (semaglutide), providing significant annual savings for patients [1][2] - The subscription model enhances patient access to branded GLP-1 therapy and supports treatment adherence [2][3] Company Overview - LifeMD is a leading provider of virtual primary care services, offering telemedicine and access to laboratory and pharmacy services across more than 200 conditions [5] - The company has a vertically integrated digital care platform and a 50-state affiliated medical group [5] Collaboration Details - The Wegovy® subscription program is an extension of LifeMD's collaboration with Novo Nordisk, which has evolved from an initial pharmacy integration to a comprehensive commercial partnership [3] - LifeMD is recognized as a telehealth provider on both the NovoCare® and Wegovy® websites, highlighting the strength of their relationship [3] Patient Benefits - Patients enrolled in the Wegovy® program through LifeMD can save up to $1,200 annually for injectable formulations and $600 for oral therapy [2] - The program offers a comprehensive care experience, including virtual visits, ongoing clinical oversight, diagnostic testing, and simplified billing [4]

Core Insights - Mink Ventures Corporation has received a grant of $93,365.81 from the Government of Ontario to support critical minerals exploration at its Warren nickel, copper, and cobalt project [1][2] - The Warren property spans 1,130 hectares and is located approximately 35 km west of Timmins, Ontario, near Mink's Montcalm project [1][4] - The recent drill program at Warren successfully intersected mineralization in all drill holes, with notable results including a massive sulphide zone returning 0.44% nickel, 0.28% copper, and 0.06% cobalt over 7.1 meters [2][4] Company Overview - Mink Ventures Corporation is focused on exploring critical minerals such as nickel, copper, and cobalt at its Warren and Montcalm projects in the Timmins area [4] - The Montcalm Project is adjacent to Glencore's former Montcalm Mine, which historically produced 3.93 million tonnes of ore with grades of 1.25% nickel, 0.67% copper, and 0.051% cobalt [4] - Both projects are drill-ready, permitted, and have good access to infrastructure, including an all-weather access road and power [4] Exploration Plans - The company plans to purchase a historical VTEM survey conducted on the Warren property and perform Maxwell plate analysis to prioritize VTEM anomalies [3] - This data will complement existing ground induced polarization and magnetic surveys, aiding in preparation for a major drilling campaign [3]

Core Insights - Cadrenal Therapeutics is advancing CAD-1005 as a lead development priority for treating heparin-induced thrombocytopenia (HIT), supported by encouraging Phase 2 data and recent FDA feedback [1][3] - The company is also exploring broader opportunities within its 12-LOX inhibitor platform for future value creation [1][3] Recent Highlights - CAD-1005 demonstrated a greater than 25% absolute reduction in thrombotic events compared to placebo in a Phase 2 study, indicating its potential as a differentiated treatment for HIT [7] - The End-of-Phase 2 meeting with the FDA clarified the regulatory path for CAD-1005, with the company currently incorporating FDA feedback into the Phase 3 trial protocol [7][3] Financial Performance - For Q4 2025, research and development expenses were $0.7 million, down from $1.5 million in Q4 2024, while general and administrative expenses decreased to $2.4 million from $2.7 million [4] - The net loss for Q4 2025 was $3.0 million, an improvement from a net loss of $4.2 million in the same quarter of 2024 [4] Cash Position - As of December 31, 2025, Cadrenal had cash and cash equivalents of $4.0 million, down from $10.0 million in 2024, and is evaluating financing options to support clinical development activities [5][12] Company Overview - Cadrenal Therapeutics is a late-stage biopharmaceutical company focused on novel therapies for life-threatening immune and thrombotic conditions, with CAD-1005 being its first-in-class 12-LOX inhibitor [8] - The company also has a broader pipeline that includes tecarfarin and frunexian, targeting chronic anticoagulation and acute hospital settings, respectively [9]